Pheast Therapeutics

Pheast Therapeutics | Services: Clinical-stage immuno-oncology company engineering macrophage checkpoint inhibitors; lead candidate PHST001 - a best-in-class antibody designed to induce macrophages to phagocytose cancer cells; pipeline targets CD24-blockade for ovarian cancer and other tumors resistant to existing immunotherapies; exploring macrophage approaches in inflammation indications beyond oncology | Leadership: Co-Founder and CEO Roy Maute; founded by the scientists who made foundational discoveries in cancer immunotherapy and innate immunity | Keywords: immuno-oncology, macrophage checkpoint, CD24, phagocytosis, PHST001, antibody therapy, innate immunity, ovarian cancer